Suscribirse

Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis - 17/08/11

Doi : 10.1016/j.amjsurg.2006.08.045 
Peter H. Lin, M.D. a, , Wei Zhou, M.D. a, Alan Dardik, M.D. b, Firas Mussa, M.D. a, Panos Kougias, M.D. a, Nasim Hedayati, M.D. a, Joseph J. Naoum, M.D. a, Hosam El Sayed, M.D. a, Eric K. Peden, M.D. a, Tam T. Huynh, M.D. a
a Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston Veterans Affairs Medical Center (112), 2002 Holcomb Blvd., Houston, TX 77030, USA 
b Department of Surgery, Yale University School of Medicine, New Haven, CT, USA 

Corresponding author. Tel.: +1-713-794-7895; fax: +1-713-794-7352.

Abstract

Background

Rheolytic mechanical thrombectomy using the AngioJet catheter (Possis Medical, Minneapolis, MN) has been shown to be effective in the treatment of deep venous thrombosis (DVT). Additional infusion of thrombolytic agents via the device creates a novel treatment strategy of pharmacomechanical thrombectomy (PMT), which further enhances thrombectomy efficacy. The purpose of the current study was to compare the treatment outcome in patients with symptomatic DVT who underwent either catheter-directed thrombolysis (CDT) or PMT intervention.

Methods

During a recent 8-year period, clinical records of all patients with symptomatic lower leg DVT undergoing catheter-directed interventions were evaluated. Patients were divided into 2 treatment groups: CDT or PMT. Comparisons were made with regards to the treatment outcome between the 2 groups.

Results

A total of 93 patients who underwent 98 catheter-directed interventions for DVT were included in the study. Among them, CDT or PMT was performed in 46 (47%) and 52 (53%) procedures, respectively. In the CDT group, complete or partial thrombus removal was accomplished in 32 (70%) and 14 (30%) cases, respectively. In the PMT cohort, complete or partial thrombus removal was accomplished in 39 (75%) and 13 (25%) cases, respectively. Venous balloon angioplasty and/or stenting in the CDT or PMT groups was necessary in 36 (78%) and 43 (82%), respectively (difference not significant [NS]). Patients in the CDT groups underwent a mean of 2.5 venograms during the hospital course, in contrast to 0.4 venograms per patient in PMT cohorts (P < .001). Immediate (<24 hours) improvement in clinical symptoms in CDT and PMT groups was achieved in 33 (72%) and 42 (81%) cases, respectively (NS). Significant reductions in the intensive care unit (ICU) and hospital lengths of stay was noted in the PMT group (0.6 and 4.6 days) when compared to the CDT group (2.4 and 8.4 days). During follow-up visits, the primary patency rates at 1 year of CDT and PMT groups were 64% and 68%, respectively (NS). Hospital cost analysis showed significant cost reduction in the PMT group compared to the CDT group (P < .01).

Conclusions

PMT with adjunctive thrombolytic therapy is an effective treatment modality in patients with significant DVT. When compared to CDT, this treatment provides similar treatment success with reduced ICU, total hospital length of stay, and hospital costs.

El texto completo de este artículo está disponible en PDF.

Keywords : Deep vein thrombosis, Thrombolysis, Thrombectomy, Endovascular treatment


Esquema


© 2006  Excerpta Medica Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 192 - N° 6

P. 782-788 - décembre 2006 Regresar al número
Artículo precedente Artículo precedente
  • How I do it: cervical access for carotid artery stenting
  • Robert W. Feldtman, Clifford J. Buckley, W. Todd Bohannon
| Artículo siguiente Artículo siguiente
  • Extended interval for retrieval of vena cava filters is safe and may maximize protection against pulmonary embolism
  • Dimitrios Stefanidis, B. Lauren Paton, David G. Jacobs, Dennis A. Taylor, Kent W. Kercher, B. Todd Heniford, Ronald F. Sing

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.